MADISON (WKOW) – Residents at Porchlight, a non-profit organization dedicated to reducing homelessness, are moving into their new home on South Blair Street. The building provides permanent housing ...
Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback